Ditchcarbon
  • Contact
  1. Organizations
  2. Aptalis Holdings Inc.
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated a month ago

Aptalis Holdings Inc. Sustainability Profile

Company website

Aptalis Holdings Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States. Founded in 2008, the company has established itself as a leader in developing innovative drug delivery systems and specialty pharmaceuticals. With a focus on enhancing patient outcomes, Aptalis operates primarily in North America and Europe, catering to diverse therapeutic areas, including gastrointestinal and respiratory health. The company’s core offerings include advanced formulations and unique delivery technologies that set them apart in a competitive market. Notable achievements include strategic partnerships and a robust pipeline of products that address unmet medical needs. Aptalis Holdings Inc. continues to solidify its market position through a commitment to research and development, driving advancements in patient care and therapeutic efficacy.

DitchCarbon Score

How does Aptalis Holdings Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

41

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

31

Industry Benchmark

Aptalis Holdings Inc.'s score of 41 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.

62%

Let us know if this data was useful to you

Aptalis Holdings Inc.'s reported carbon emissions

Inherited from Allergan plc

Aptalis Holdings Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of AbbVie Inc., which influences its climate commitments and reporting practices. While Aptalis Holdings Inc. does not have its own documented reduction targets, it inherits sustainability initiatives from its parent company, AbbVie Inc. This includes participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are aimed at reducing greenhouse gas emissions in line with global climate goals. As part of its corporate family, Aptalis may also align with broader climate strategies and commitments established by AbbVie, which are designed to enhance environmental performance and accountability. However, specific details regarding Aptalis's individual climate pledges or reduction targets remain unspecified. In summary, while Aptalis Holdings Inc. does not provide direct emissions data or specific reduction targets, it is positioned within a corporate structure that prioritises climate action through inherited initiatives from AbbVie Inc.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

2005201020112012201520162017
Scope 1
28,218,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 2
59,189,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 3
-
-
-
-
000,000,000
000,000,000
000,000,000

How Carbon Intensive is Aptalis Holdings Inc.'s Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Aptalis Holdings Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Aptalis Holdings Inc.'s Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Aptalis Holdings Inc. is in US, which has a low grid carbon intensity relative to other regions.

Aptalis Holdings Inc.'s Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Aptalis Holdings Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Aptalis Holdings Inc.'s Emissions with Industry Peers

Johnson And Johnson

US
•
Pharmaceutical Preparation Manufacturing
Updated about 20 hours ago

Vertex Pharmaceuticals

US
•
Pharmaceutical Preparation Manufacturing
Updated 9 days ago

Teva Puerto Rico LLC

US
•
Pharmaceutical Preparation Manufacturing
Updated 15 days ago

Ferring Inc.

CA
•
Pharmaceutical Preparation Manufacturing
Updated 24 days ago

Biogen

US
•
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Meda AB

SE
•
Pharmaceutical Preparation Manufacturing
Updated about 2 months ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251031.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy